Cowen analyst Phil Nadeau reiterated an Outperform rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $55.00 (from $45.00), saying the company is gearing up for a catalyst-rich 6 months.

Nadeau commented, "NBIX's pipeline should yield a number of catalysts over the next 6 months including results from: (1) Elagolix's Ph. IIb in uterine fibroids (Q3); (2) '854's pivotal Ph. III in tardive dyskinesia (Q4); (3) '854's Ph. Ib in Tourette's (H2) and Elagolix's second Ph. III in endometriosis (Q1:16). Based on the progress of NBIX's pipeline today we are increasing our price target from $45 to $55."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $50.66 yesterday.